Table 3 Hemostatic data for the two groups

Heparin doses

 Mean dose (IU/kg/h)

11 [7–16]

12 [8–15]

0.9

 Dose at the occurrence of bleeding (IU/kg/h)

13 [7–16]

–

–

Anti-Xa (IU/mL)

 Mean anti-Xa during ECMO support

0.38 [0.29–0.67]

0.33 [0.22–0.42]

0.01

 Maximum anti-Xa

0.83 [0.47–1.46]

0.66 [0.36–0.91]

0.05

 Anti-Xa at the occurrence of bleeding

0.33 [0.15–0.50]

–

–

Platelet function

 Minimum platelets during ECMO (/mm³)

93 [57–162]

91 [60–120]

0.6

 Platelets at the occurrence of bleeding (/mm³)

109 [63–178]

–

–

 Antiplatelet agents during ECMO, n (%)

24 (68)

59 (69)

0.9

Hemorrhagic complications

 Needing 2 packed RBC or more / drop of hemoglobin of 2 g/dL or more

23 (66)

–

–

 Characterized by its location

12 (34)

–

–

 Needing specific intervention

11 (31)

–

–

 Delay between ECMO and hemorrhage (days)

3 [2–6]

–

–

Type of bleeding, n (%)

 Intracerebral hemorrhage

9 (26)

–

–

 Bleeding on cannula site

14 (40)

–

–

 Oropharyngeal bleeding

7 (20)

–

–

 Pericardial bleeding

3 (9)

–

–

 Pulmonary hemorrhage

2 (6)

–

–

 Hemothorax

2 (6)

–

–

 Gastrointestinal bleeding

1 (3)

–

–

 Hematuria

1 (3)

–

–

 Massive metrorrhagia

1 (3)

–

–

 Multiple-site bleeding

7 (20)

–

–

Bleeding leading to death, n (%)

8 (23)

–

–

Number of packed RBC during ECMO

7 [4–13]

2 [0–5]

< 0.0001

Thrombotic complications, n (%)

8 (23)

20 (23)

0.7

 Ischemic stroke

4 (11)

6 (7)

 Membrane oxygenation replacement needed

2 (8)

4 (5)

 Limb ischemia

0 (0)

3 (3)

 Deep vein thrombosis

3 (9)

8 (9)

30-day mortality, n (%)

17 (48)

20 (24)

0.009